on FSD Pharma Inc.
FSD Pharma Submits Clinical Trial Protocol for Unbuzzd™ in Acute Alcohol Intoxication
FSD Pharma Inc. has confirmed the submission of a clinical trial protocol to the institutional review board in the USA for Unbuzzd™. This protocol aims to assess the safety and efficacy of Unbuzzd™ in healthy volunteers during the METAL-2 trial. Recruitment will commence following IRB approval. The trial will use a crossover design to study Unbuzzd™'s ability to alleviate acute alcohol intoxication effects.
Dr. Andrzej Chruscinski, Vice-President of Clinical and Scientific Affairs at FSD Pharma, expressed enthusiasm about reaching this milestone in the clinical trial for Unbuzzd™.
R. E.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all FSD Pharma Inc. news